In PC malignancies, BCMA functions primarily as a membrane receptor in key signaling cascades via NF-kB, MAPK/ERK, p38, and JNK/Elk-1 for the cell growth, proliferation, and survival of committed B lymphocytes and PCs [3,5], as well as in the maintenance of an immunosuppressive tumor microenvironment in multiple myeloma (MM) [7,9]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.